{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-009141","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2022-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.624425+00:00","generated_at":"2026-06-25T21:10:53.210061+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Monte Rosa Q1 net loss $23.9M; IND for MRT-2359 expected mid-2022","bullets":["Net loss $23.9M for Q1 2022 vs $12.3M in Q1 2021; R&D spend $17.9M.","Cash position $322.5M as of March 31, 2022; runway into late 2024.","IND submission for GSPT1 degrader MRT-2359 on track for mid-2022; initial focus on NSCLC and SCLC.","Preclinical data at AACR 2022 support MRT-2359 in Myc-driven solid tumors.","New collaboration with EPFL to integrate AI engine with MaSIF technology for novel degrader discovery."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-009141","json":"https://secwatch.observer/filing/0000950170-22-009141.json","markdown":"https://secwatch.observer/filing/0000950170-22-009141.md","text":"https://secwatch.observer/filing/0000950170-22-009141.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000095017022009141/0000950170-22-009141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000095017022009141/glue-20220511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:10:53.210061+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}